New treatment option for Paroxysmal Atrial Fibrillation
Official title Atrial Anomalies Predict Silent Atrial Fibrillation Detected by Implantable Cardiac Monitor in Cryptogenic Stroke
ClinicalTrials.gov ID: NCT06542770
What this study is testing
- What it's testing
- Cryptogenic stroke (CS) causes about 30% of admissions to a stroke unit. Silent paroxysmal atrial fibrillation (PAF) is believed to be the underlying cause of a significant proportion of patients.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 50 to 89
You may be able to join if
- Acute ischemic stroke or transient ischemic attack (TIA) from January 2022 to July 2023
- Age between 50 and 89 years;
- Undetermined origin at hospital admission according to the SSS-TOAST criteria (2):
- Absence of major structural heart disease by cardiac ultrasound (normal global and segmental left ventricle contraction, absence of...
- Absence of AF during 48h ECG-monitoring
You likely can't join if
- Patients with a history of hemorrhagic stroke;
- Presence with prior atrial fibrillation or atrial flutter;
- Permanent contraindication or indication for OAC for other reasons;
- Recent (\<1 month) major surgery or cardiac events;
- Presence of severe cardiac abnormalities;
- Patients with life expectancy \ 4).
See the full eligibility criteria
- Acute ischemic stroke or transient ischemic attack (TIA) from January 2022 to July 2023
- Age between 50 and 89 years;
- Undetermined origin at hospital admission according to the SSS-TOAST criteria (2):
- Absence of major structural heart disease by cardiac ultrasound (normal global and segmental left ventricle contraction, absence of valvular/rheumatic disease, absence of intracardiac shunts)
- Absence of AF during 48h ECG-monitoring
- Absence of major anomalies in the supra-aortic trunks ultrasound.
- Patients with a history of hemorrhagic stroke;
- Presence with prior atrial fibrillation or atrial flutter;
- Permanent contraindication or indication for OAC for other reasons;
- Recent (\<1 month) major surgery or cardiac events;
- Presence of severe cardiac abnormalities;
- Patients with life expectancy \ 4).
The study team makes the final eligibility decision.
Where it's taking place
- Barcelona, Spain
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 50 years to 89 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Barcelona, Spain. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.